LOTUS REPORTS ITS BEST QUARTER EVER WITH THE BIGGEST LAUNCH IN ITS HISTORY

Lotus Pharmaceutical (1795: TT), a multinational pharmaceutical company, today reported its financial results for the third quarter ended 30 September 2022.

THIRD QUARTER FINANCIAL HIGHLIGHTS:

* Third quarter 2022 is the best quarter ever in the Companys history, majorly driven by the successful launch of Lenalidomide in the US – the biggest launch in Lotus history so far. Basic EPS for the first nine months ended 30 September 2022 totaled NT$10.96, setting the course for the Company to achieve another record year in 2022.
* Consolidated net sales were NT$5,389 million, representing a growth of 85.2% over the last quarter and 76.3% versus prior year period.
* Gross margin rose to 67.9%, driven by product mix with higher contribution from more profitable export oncology products during the quarter.
* Comparing to the prior year, operating profits grew by 353%, to NT$2,641 million, with 49.0% operating margin for the quarter, mainly driven by higher gross margin.
* Historic high third quarter EPS of NT$7.97 and first 9 months basic EPS of NT$10.96.

* – Export Business was the main growth driver, contributed by the successful launch of Lenalidomide (generic of Revlimid) in the US, as well as the first delivery to Brazil, the largest market in Latin America. Sales from Export increased 245% compared to last quarter and 183% compared to same

Media enquiries:
Lara Omarsdottir, Public Relations
+354 659 9166
media@aztiq.comlara@aztiq.isPhoto: mma.prnewswire.com/media/1944086/Lotus_new_building.jpg
Photo: mma.prnewswire.com/media/1944087/Lotus_Lobby.jpg
View original content:www.prnewswire.co.uk/news-releases/lotus-reports-its-best-quarter-ever-with-the-biggest-launch-in-its-history-301675349.html

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS. www.ots.at
© Copyright APA-OTS Originaltext-Service GmbH und der jeweilige Aussender